Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Melphalan at a dose of 200 mg/m(2) is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m(2) is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m(2...

Descripción completa

Detalles Bibliográficos
Autores principales: Auner, Holger W., Iacobelli, Simona, Sbianchi, Giulia, Knol-Bout, Cora, Blaise, Didier, Russell, Nigel H., Apperley, Jane F., Pohlreich, David, Browne, Paul V., Kobbe, Guido, Isaksson, Cecilia, Lenhoff, Stig, Scheid, Christof, Touzeau, Cyrille, Jantunen, Esa, Anagnostopoulos, Achilles, Yakoub-Agha, Ibrahim, Tanase, Alina, Schaap, Nicolaas, Wiktor-Jedrzejczak, Wieslaw, Krejci, Marta, Schönland, Stefan O., Morris, Curly, Garderet, Laurent, Kröger, Nicolaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830386/
https://www.ncbi.nlm.nih.gov/pubmed/29217776
http://dx.doi.org/10.3324/haematol.2017.181339

Ejemplares similares

Ejemplares similares